In an 86‑year‑old woman with macrocytic anemia (MCV 105.6 fL), low red blood cell count, normal hemoglobin, and hemoglobin A1c 6.4 %, what are the likely causes and what diagnostic work‑up and treatment should be pursued?

Macrocytic Anemia in an 86-Year-Old Woman

This patient requires immediate evaluation for vitamin B12 and folate deficiency, followed by assessment for myelodysplastic syndrome (MDS) if nutritional causes are excluded.

Understanding the Laboratory Findings

Your patient presents with:

• Macrocytosis: MCV 105.6 fL (significantly elevated above normal 80-95 fL)
• Borderline low RBC: 3.80 M/uL (reference 4.20-5.40)
• Normal hemoglobin: 13.2 g/dL (within 12.0-16.0 range)
• Elevated MCH: 34.7% (above 26.0-32.0)
• HbA1c 6.4%: Prediabetes range

The normal hemoglobin despite low RBC count occurs because the enlarged red cells compensate volumetrically—fewer but bigger cells maintain adequate oxygen-carrying capacity temporarily.

Most Likely Causes in This Age Group

According to morphologic classification, macrocytic anemia (MCV >100 fL) is most commonly megaloblastic, indicating vitamin B12 or folate deficiency 1. However, in elderly patients, the differential broadens significantly:

Primary Considerations:

1. Vitamin B12 deficiency (most common megaloblastic cause) 1, 2

   • Particularly common in elderly due to decreased intrinsic factor, atrophic gastritis, or malabsorption
   • Can cause neurologic symptoms (paresthesias, ataxia, cognitive changes)

2. Myelodysplastic syndrome (MDS)

   • Leading cause of macrocytic anemia in studies of elderly patients (19.3% of cases) 3
   • Age 86 is peak demographic for MDS
   • Can present with isolated macrocytosis before frank anemia develops

3. Folate deficiency (less common in developed countries due to food fortification) 1

4. Medication-induced (hydroxyurea, methotrexate, anticonvulsants) 1

5. Alcohol use/liver disease 1, 2

6. Hypothyroidism 2

Critical Diagnostic Algorithm

Step 1: Peripheral Blood Smear Review (IMMEDIATE)

Essential first step 1. Look specifically for:

• Hypersegmented neutrophils (≥5 lobes): Pathognomonic for megaloblastic anemia
• Oval macrocytes: Suggest B12/folate deficiency
• Round macrocytes: Suggest liver disease, alcoholism, or MDS
• Dysplastic features: Suggest MDS (pseudo-Pelger-Huët cells, hypolobulated megakaryocytes)

Step 2: Initial Laboratory Work-Up

Order simultaneously 1:

For Megaloblastic Causes:

• Serum vitamin B12 level
• Serum folate level
• Methylmalonic acid (MMA) and homocysteine if B12 borderline (increases sensitivity)

For Production Assessment:

• Reticulocyte count with reticulocyte index (RI) 1
  • Low RI (<1.0-2.0): Decreased RBC production → suggests B12/folate deficiency, MDS, or bone marrow dysfunction
  • High RI: Suggests hemolysis or blood loss (less likely here given presentation)

Additional Tests:

• TSH (hypothyroidism screening)
• Liver function tests (AST, ALT, bilirubin)
• Comprehensive metabolic panel including creatinine (renal disease can cause macrocytosis)

Step 3: Detailed History and Physical Examination

History must include 1:

• Neurologic symptoms: Paresthesias, balance problems, memory changes (B12 deficiency)
• Dietary history: Vegan diet, malnutrition (B12/folate)
• Alcohol consumption (common cause of macrocytosis)
• Medication review: Metformin (impairs B12 absorption), proton pump inhibitors, anticonvulsants
• GI symptoms: Diarrhea, weight loss (malabsorption)
• Prior gastric surgery (loss of intrinsic factor)
• Fatigue severity and duration

Physical examination focus 1:

• Neurologic exam: Posterior column signs (vibration/proprioception loss), ataxia
• Glossitis, angular cheilitis (B12/folate deficiency)
• Jaundice (hemolysis, liver disease)
• Hepatosplenomegaly
• Petechiae (thrombocytopenia suggesting MDS)

Step 4: If Initial Work-Up Negative → Bone Marrow Evaluation

Bone marrow aspiration and biopsy with cytogenetics is indicated when 1, 4:

• B12 and folate levels are normal
• No reversible cause identified
• Persistent or worsening macrocytosis
• Other cytopenias develop
• Dysplastic features on peripheral smear

This evaluates for MDS, which requires morphologic assessment and cytogenetic analysis for diagnosis and risk stratification 4.

Treatment Approach

If Vitamin B12 Deficiency Confirmed:

• Cyanocobalamin 1000 mcg IM daily × 1 week, then weekly × 4 weeks, then monthly maintenance
• Oral high-dose B12 (1000-2000 mcg daily) is alternative if no neurologic symptoms
• Monitor CBC in 1-2 months for reticulocyte response and MCV normalization

If Folate Deficiency Confirmed:

• Folic acid 1-5 mg daily orally
• NEVER treat folate deficiency without excluding B12 deficiency first—folate can mask B12 deficiency while neurologic damage progresses

If MDS Diagnosed:

Treatment depends on risk stratification (IPSS-R score) 4:

• Lower-risk MDS with anemia: Consider erythropoiesis-stimulating agents (ESAs) if serum EPO ≤500 mU/mL, or luspatercept-aamt
• Higher-risk MDS: Hypomethylating agents (azacitidine, decitabine) or allogeneic stem cell transplant evaluation

Important Caveats

Regarding the HbA1c of 6.4%:

Macrocytosis can falsely lower HbA1c values 5. The elevated MCH (34.7%) in this patient may cause underestimation of glycemic control. Studies show that for every 1 pg increase in MCH, the odds of correctly identifying dysglycemia decrease by 10-14% 5. Consider confirming diabetes status with fasting glucose or oral glucose tolerance test rather than relying solely on HbA1c 6, 7.

Common Pitfalls to Avoid:

1. Do not assume macrocytosis equals B12 deficiency without testing—MDS is equally common in this age group 3

2. Do not overlook medication history—many drugs cause macrocytosis without true anemia

3. Do not delay bone marrow biopsy if initial work-up is unrevealing—early MDS diagnosis affects prognosis and treatment options

4. Do not treat empirically without confirming deficiency—this obscures diagnosis and can worsen outcomes (especially folate masking B12 deficiency)

5. Do not ignore the "normal" hemoglobin—compensated macrocytosis can deteriorate rapidly, and underlying MDS may progress

Prognosis Considerations

• If nutritional deficiency: Excellent prognosis with replacement therapy; expect reticulocytosis in 3-5 days and MCV normalization in 2-3 months
• If MDS: Prognosis depends on risk category; lower-risk MDS median survival 3-6 years, higher-risk <1 year without treatment 4, 8
• Quality of life: Untreated B12 deficiency causes irreversible neurologic damage; MDS-related anemia significantly impacts functional status in elderly patients

Begin with peripheral smear review and B12/folate levels immediately—these are low-cost, high-yield tests that guide all subsequent management decisions.